Highlights
- •Soft-tissue sarcomas may not shrink in response to chemotherapy despite adequate treatment.
- •Decreased attenuation or contrast enhancement more accurately predicts sarcoma treatment response.
- •Quantitative MRI of sarcomas can estimate necrosis and viable tumor volume to assess treatment response.
Abstract
Soft-tissue sarcomas are a heterogeneous class of tumors that exhibit varying degrees
of cellularity and cystic degeneration in response to neoadjuvant chemotherapy. This
creates unique challenges in the radiographic assessment of treatment response when
relying on conventional markers such as tumor diameter (RECIST criteria). In this
case series, we provide a narrative discussion of technique development for whole
tumor volume quantitative magnetic resonance imaging (q-MRI), highlighting cases from
a small pilot study of 8 patients (9 tumors) pre- and post-neoadjuvant chemotherapy.
One of the methods of q-MRI analysis (the “constant-cutoff” technique) was able to
predict responders versus non-responders based on percent necrosis and viable tumor
volume calculations (p = 0.05), respectively. Our results suggest that q-MRI of whole tumor volume contrast
enhancement may have a role in tumor response assessment, although further validation
is needed.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Imaging and response in soft tissue sarcomas.Hematol Oncol Clin North Am. 2005; 19 ([vi]): 471-487
Fletcher CDM, Bridge JA, Hogendoorn PCW, Fletcher CDM, Bridge JA, Hogendoorn P. WHO classification of tumours of soft tissue and bone. Lyon, France: International Agency for Research on Cancer (I A R C) (UN), 2013.
- More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments.Am Soc Clin Oncol Educ Book. 2018; 38: 925-938
- Historic evidence and future directions in clinical trial therapy of solid tumors.Oncology (Williston Park). 2006; 20: 10-18
- New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.J Natl Cancer Inst. 2000; 92: 205-216
- Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.J Clin Oncol. 2008; 26: 1346-1354
- Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST.AJR Am J Roentgenol. 2012; 198: 737-745
- Hemorrhage simulating tumor growth in malignant fibrous histiocytoma at MR imaging.Radiology. 1991; 181: 398-400
- Soft-tissue sarcomas: assessment of MRI features correlating with histologic grade and patient outcome.Radiology. 2019; 291: 710-721
- High-grade soft-tissue sarcomas: tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.Radiology. 2009; 251: 447-456
- FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.Clin Cancer Res. 2009; 15: 2856-2863
- Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).Int J Hyperthermia. 2009; 25: 289-298
- Validation of radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas: Japanese Orthopaedic Association Committee on Musculoskeletal Tumors Cooperative Study.J Orthop Sci. 2008; 13: 304-312
Schuetze SM, Eary JF, Griffith KA, et al. FDG PET but not RECIST agrees with histologic response of soft tissue sarcoma to neoadjuvant chemotherapy. Journal of Clinical Oncology. 2005; 23(16_suppl):9005–9005.
- Response assessment in clinical trials: implications for sarcoma clinical trial design.Oncologist. 2008; 13: 14-18
- Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.J Clin Oncol. 2007; 25: 1753-1759
- Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.Cancer. 2012; 118: 5857-5866
- Selection of response criteria for clinical trials of sarcoma treatment.Oncologist. 2008; 13: 32-40
- Contrast-enhanced Sonography for monitoring neoadjuvant chemotherapy in soft tissue sarcomas.J Ultrasound Med. 2015; 34: 1489-1499
- T2-based MRI delta-radiomics improve response prediction in soft-tissue sarcomas treated by neoadjuvant chemotherapy.J Magn Reson Imaging. 2019; 50: 497-510
Article info
Publication history
Published online: February 27, 2020
Accepted:
February 25,
2020
Received in revised form:
February 18,
2020
Received:
September 7,
2019
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
